Fc-relaxin fusion protein (TX45)
Protein / enzyme therapeutic
Also known as TX000045
Evidence outlook
Pulmonary Hypertension due to Left Heart Disease: mid-stage studies underway, no completed readout
In Pulmonary Hypertension due to Left Heart Disease, Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. Studies in other indications have read out; see the trials and Regulatory events below.
Also in development:Pulmonary Hypertension Associated with Interstitial Lung Disease · Phase 2
Company guidance: topline data expected January 2027 (Tectonic Therapeutic, 5 Nov 2026). “Topline results from the APEX Phase 2 clinical trial of TX45 in pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-HFpEF”) are anticipated by the end of January 2027” Source ↗
Company guidance: interim data expected second half of 2027 (Tectonic Therapeutic, 5 Nov 2026). “Dosed first patient in the ALPINE Phase 2a clinical trial of TX45 in pulmonary hypertension associated with interstitial lung disease (“PH-ILD”) in October 2026, with interim topline results expected in the second half of 2027” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06616974 NCT06616974 · Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction Registry: NCT06616974 | 2 | Mean change from baseline in Pulmonary Vascular Resistance (PVR) in participants with a combined pre- and post-capillary pulmonary hypertension (CpcPH). (Baseline up to Week 24 post first dose); Assess safety of TX000045 by the incidence of adverse events, adverse events of special interest and SAEs. (Baseline up to Week 30 post first dose); Number of participants with abnormal laboratory values and/or adverse events that are related to treatment. (Baseline up to Week 30 post first dose); Number of participants with treatment-related adverse events. (Baseline up to Week 30 post first dose); Number of participants with changes in the physical examination findings. (Baseline to Week 30 post first dose) 2026-11-24 | In progress: results expected 24 Nov 2026 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (2)
What this study did
What this study did
Competitive landscape
Other Relaxin receptor (RXFP1) / relaxin drugs
Pexerelgon, R2R01. Compare all 3 Relaxin receptor (RXFP1) / relaxin drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Pulmonary Hypertension Associated with Interstitial Lung Disease: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Fc-Relaxin Fusion Protein (TX45): this drug | Phase 2 | Protein / enzyme therapeutic | Relaxin receptor (RXFP1) / relaxin | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (Tyvaso DPI) | Approved | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (Tyvaso) | Approved | Small molecule | IP receptor (prostacyclin pathway) | Reliable signal | NCT02630316: Change in peak 6-minute walk distance from baseline to week 16: inhaled treprostinil median +6.0 m vs placebo -9.0 m (n=163 each); Hodges-Lehmann difference 21.0 m (95% CI 7.0 to 37.0), p=0.0043 (CT.gov posted results). | |
| Treprostinil (Yutrepia, Liquidia) | Approved | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Mosliciguat | Phase 3 | Small molecule | Soluble guanylate cyclase | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (L606) | Phase 3 | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| LAM-001 | Phase 2 | Small molecule | mTOR (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| Mirivadelgat | Phase 2 | Small molecule | ALDH2 | not yet graded | No reviewed efficacy summary in this indication | |
| Pexerelgon | Phase 2(overall) | Small molecule | Relaxin receptor (RXFP1) / relaxin | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| R2R01 | Phase 2(overall) | Peptide | Relaxin receptor (RXFP1) / relaxin | Weak signal(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Fc-relaxin fusion protein (TX45) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
November 2026 (1)
What to watch
2027 (1)
November 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent